Stockscreener 앱 받기
1.30%
시간 외 거래:
전일 마감가:
$4.63
열려 있는:
$4.65
하루 거래량:
2.23M
Relative Volume:
0.47
시가총액:
$572.31M
수익:
$409.00K
순이익/손실:
$-101.35M
주가수익비율:
-2.7866
EPS:
-1.64
순현금흐름:
$-71.49M
1주 성능:
-7.11%
1개월 성능:
+12.84%
6개월 성능:
+26.24%
1년 성능:
-26.53%
1일 변동 폭
$4.47
$4.70
1주일 범위
$4.47
$5.085
52주 변동 폭
$2.90
$7.73
알티뮨 Stock (ALT) Company Profile
명칭
Altimmune Inc
전화
(240) 654-1450
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
4.57 | 579.82M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
알티뮨 Stock (ALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-07-10 | 재개 | Goldman | Sell |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-04-29 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-24 | 개시 | Goldman | Neutral |
| 2023-03-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-02 | 개시 | H.C. Wainwright | Buy |
| 2021-02-11 | 개시 | Guggenheim | Buy |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-11-12 | 재확인 | B. Riley Securities | Buy |
| 2020-09-25 | 개시 | B. Riley FBR | Buy |
| 2020-08-14 | 개시 | Evercore ISI | Outperform |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-28 | 개시 | JMP Securities | Mkt Outperform |
| 2020-02-24 | 재개 | ROTH Capital | Buy |
| 2019-07-19 | 개시 | ROTH Capital | Buy |
| 2017-10-09 | 개시 | Piper Jaffray | Overweight |
모두보기
알티뮨 주식(ALT)의 최신 뉴스
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Altimmune gains on FDA breakthrough designation for MASH therapy - MSN
Altimmune, Inc. Closes $75 Million Registered Direct Offering to Advance Pemvidutide Development for Liver Diseases - Quiver Quantitative
Altimmune, Inc. (ALT) gains analyst support ahead of phase 3 MASH development - MSN
Is Altimmune Inc a strong candidate for buy and hold2025 Growth vs Value & AI Powered Market Entry Ideas - baoquankhu1.vn
Altimmune Sets 2026 Annual Stockholder Meeting Timeline - TipRanks
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 (NASDAQ:ALT) - Seeking Alpha
Forecast Cut: Is Altimmune Inc a strong candidate for buy and holdTake Profit & Smart Swing Trading Techniques - baoquankhu1.vn
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development - Insider Monkey
Growth Report: Is Altimmune Inc a strong candidate for buy and holdJuly 2025 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
Altimmune stock price ends higher after $75 million deal closes as Vanguard filing adds focus - TechStock²
Altimmune, Inc. (ALT) Stock Analysis: Exploring a 246% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Altimmune closes $75 million registered direct offering By Investing.com - Investing.com India
Altimmune (NASDAQ:ALT) Trading Up 7.2%Here's What Happened - MarketBeat
Is Altimmune Inc. a potential multi baggerAnalyst Upgrade & High Accuracy Trade Signal Alerts - mfd.ru
Altimmune closes $75 million registered direct offering - Investing.com
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock - The Manila Times
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock - Benzinga
Biotech Altimmune raises $75M for Phase 3 MASH liver drug trial - Stock Titan
Altimmune (NASDAQ:ALT) Rating Increased to Strong-Buy at Barclays - MarketBeat
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Sahm
Altimmune raises $75 million to fund MASH therapy development By Investing.com - Investing.com Nigeria
ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon - Stocktwits
Altimmune Announces $75 Million Registered Direct Equity Offering - TipRanks
Altimmune Signs Multiple Material Agreements - TradingView
Altimmune: Why Breakthrough Status Isn't A 'Buy' Signal Just Yet (NASDAQ:ALT) - Seeking Alpha
Altimmune (ALT) Shares Slide On $75 Million Stock Offering - Benzinga
Altimmune prices $75M direct offering - MSN
Altimmune (NASDAQ:ALT) Shares Gap DownHere's Why - MarketBeat
Altimmune Stock Volatility Spurs Investor Attention - StocksToTrade
Altimmune’s Recent Developments and Market Impact - timothysykes.com
Altimmune shares slide after $75 million registered direct offering - MSN
Altimmune stock falls after announcing $75 million direct offering By Investing.com - Investing.com South Africa
Altimmune stock falls after announcing $75 million direct offering - Investing.com
Qorvo, Altimmune, United Microelectronics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Altimmune Prices $75 Million Registered Direct Offering - marketscreener.com
Biotech Altimmune raises $75M to prepare Phase 3 MASH liver trial - Stock Titan
Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline - TipRanks
Altimmune Prices $75 Mln Of Share Offering; Stock Down - Nasdaq
Altimmune (ALT) Prepares for Phase 3 Trial with New Funding - GuruFocus
Altimmune Secures $75M from Institutional Investor in Direct Offering - Intellectia AI
Altimmune (ALT) Secures $75M in Direct Offering to Fund Phase 3 Trial - GuruFocus
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock - The Manila Times
Trend Recap: Will Altimmune Inc stock hit new highs in YEAR - baoquankhu1.vn
Altimmune raises $75 million to fund MASH therapy development - Investing.com
Altimmune, Inc. Announces $75 Million Registered Direct Offering to Support Phase 3 Trial for Pemvidutide - Quiver Quantitative
알티뮨 (ALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):